Language selection

Search

Details for: REMICADE

Company: JANSSEN INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02244016REMICADEINFLIXIMAB100 MG / VIALPOWDER FOR SOLUTIONINTRAVENOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Safety Review - REMICADE (infliximab) - Evaluating for the Risk of Cancer (Lymphoma, Hepatosplenic T-Cell Lymphoma, and Leukemia)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Summary Safety Review - REMICADE (infliximab) - Assessing the potential risk of a blistering skin condition known as linear IgA bullous dermatosis

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: